知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

47 records (took 0.076 seconds)

    Humanized anti-prostate stem cell antigen monoclonal antibody
    2.
    发明授权
    Humanized anti-prostate stem cell antigen monoclonal antibody 有权
    人源化抗前列腺干细胞抗原单克隆抗体

    公开(公告)号：US08088908B2

    公开(公告)日：2012-01-03

    申请号：US11432304

    申请日：2006-05-10

    Applicant: Mark A. Sherman ,  Anna M. Wu ,  Robert E. Reiter

    Inventor： Mark A. Sherman ,  Anna M. Wu ,  Robert E. Reiter

    IPC: C07H21/04

    CPC classification number: C07K16/3069 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565

    Abstract: Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA.

    Abstract translation: 前列腺干细胞抗原（PSCA）在大多数前列腺癌患者中表达，使其成为癌症免疫治疗的理想靶标。 鼠单克隆抗体1G8以纳摩尔亲和力结合PSCA，但其作为治疗剂的功效受到HAMA反应的产生的限制。 本发明公开了大部分小鼠来源的表位已被除去的人源化1G8抗体。 这些人源化抗体以高亲和力和特异性结合PSCA，并已显示可以减少人膀胱肿瘤的裸鼠模型。 这些特征使得本发明的人源化抗体用于治疗和检测表达PSCA的肿瘤的吸引剂。

    PSCA antibodies and hybridomas producing them
    9.
    发明授权
    PSCA antibodies and hybridomas producing them 有权
    PSCA抗体和产生它们的杂交瘤

    公开(公告)号：US06258939B1

    公开(公告)日：2001-07-10

    申请号：US09203939

    申请日：1998-12-02

    Applicant: Robert E. Reiter ,  Owen N. Witte

    Inventor： Robert E. Reiter ,  Owen N. Witte

    IPC: C07K1630

    CPC classification number: C07K16/3069 ,  A61K2039/505 ,  C07K14/4748 ,  C07K14/705 ,  G01N33/57434

    Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.

    Abstract translation: 本发明提供了一种新的前列腺细胞表面抗原，其命名为前列腺干细胞抗原（PSCA），其在前列腺癌的所有阶段中广泛过表达，包括高级前列腺上皮内瘤变（PIN），雄激素依赖性和雄激素依赖性 前列腺肿瘤。

Patent Agency Ranking